Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Vasc Res ; 44(6): 471-82, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17657163

RESUMO

BACKGROUND/AIMS: We investigated whether the tissue transglutaminase inhibitor cystamine is able to inhibit remodelling of small arteries in vivo, a possibility suggested by recent in vitro experiments. METHODS: Using osmotic minipumps, phenylephrine, cystamine and/or amlodipine were infused for 1-2 weeks into 9-week-old Wistar rats. Small arteries were then removed for pressure myograph investigation. RESULTS: Phenylephrine infusion caused inward remodelling of the small arteries compared to vehicle infusion. The remodelling was abolished by concomitant infusion with cystamine; blood pressure was unaffected. Second, we investigated whether cystamine was able to inhibit outward remodelling. Rats were first infused with phenylephrine for 1 week, and some were infused for a further week with amlodipine with or without cystamine. Amlodipine caused 24% outward remodelling compared to vessels from rats at completion of the phenylephrine infusion. The outward remodelling was attenuated 86% by concomitant cystamine infusion. A series of in vitro experiments supported the inhibitory action of cystamine on tissue transglutaminase. CONCLUSION: The ability of cystamine to inhibit inward remodelling independent of blood pressure is consistent with a role of tissue transgluaminase in this process. It remains to be determined if the ability of cystamine to inhibit outward remodelling also involves inhibition of tissue transglutaminase.


Assuntos
Anlodipino/farmacologia , Anti-Hipertensivos/farmacologia , Cistamina/farmacologia , Inibidores Enzimáticos/farmacologia , Proteínas de Ligação ao GTP/antagonistas & inibidores , Hipertensão/tratamento farmacológico , Artérias Mesentéricas/efeitos dos fármacos , Transglutaminases/antagonistas & inibidores , Anlodipino/administração & dosagem , Anlodipino/uso terapêutico , Animais , Anti-Hipertensivos/administração & dosagem , Anti-Hipertensivos/uso terapêutico , Pressão Sanguínea/efeitos dos fármacos , Colágeno/metabolismo , Cistamina/administração & dosagem , Cistamina/uso terapêutico , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/uso terapêutico , Proteínas de Ligação ao GTP/metabolismo , Géis , Frequência Cardíaca/efeitos dos fármacos , Hipertensão/enzimologia , Hipertensão/patologia , Hipertensão/fisiopatologia , Imuno-Histoquímica , Bombas de Infusão , Masculino , Artérias Mesentéricas/enzimologia , Artérias Mesentéricas/patologia , Microscopia Confocal , Fenilefrina , Proteína 2 Glutamina gama-Glutamiltransferase , Ratos , Ratos Wistar , Transglutaminases/metabolismo , Vasoconstrição/efeitos dos fármacos , Vasoconstritores
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA